Viking Therapeutics Faces Investor Doubt Amid VK2735's Promising Prospects
PILLAR DIAGNOSTIC // WEEK 14
“Machine forecasts for VK2735’s blockbuster revenue are clashing with early tape behavior, where a 42% post‐trial plunge signals that institutions are already repricing downside before growth assumptions converge. This sell-off is likely capping near-term upside until new data resolves model conflicts.”
Proposed action
Avoid adding new long exposure and consider hedging existing positions.
THE MECHANICS
Tape & flow
Sharp 42% one-day collapse following mid-stage trial results is contrasted by building long positioning ahead of Phase III and FDA approval catalysts, highlighting volatile tape with uneven liquidity.
THE MACHINE
Operational momentum
VK2735 is advancing rapidly through Phase III trials in both subcutaneous and oral forms, setting up a shift from current losses toward over $118 million in revenue and $12.9 million in earnings by 2029, with expectations of eventual multi-billion-dollar obesity drug sales.
THE MAP
Structure & constraints
VK-2735 focuses on dual GLP-1 and GIP receptor activation to treat metabolic ailments such as obesity.
THE MOOD
Consensus & positioning
Broad investor enthusiasm is driven by belief that VK2735 could match leading dual GLP-1/GIP therapies, supported by strong enrollment in Phase 3 trials and potential acquisition interest, yet tempered by concerns over safety and tolerability in oral studies, regulatory and execution risks, funding challenges and bearish earnings forecasts ahead of pivotal data.
